SCHEMBL16400736

SCHEMBL16400736

C=CCC1(C)OCC(COC(F)F)N(Cc2ccccc2)C1=O

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 1/20 0.34
MAPT P10636 2/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
ELANE P08246 2/20 0.32
CTSG P08311 1/20 0.32
PRTN3 P24158 1/20 0.32
HCRTR1 O43613 1/20 0.31
HCRTR2 O43614 1/20 0.31
P2RX7 Q99572 2/20 0.31
GAA P10253 1/20 0.30
MEN1 O00255 1/20 0.30
ALOX12 P18054 1/20 0.30
KMT2A Q03164 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
BCHE P06276 1/20 0.30
TMEM97 Q5BJF2 1/20 0.30
SIGMAR1 Q99720 1/20 0.30
LMNA P02545 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17691475 0.91 HSD11B1 (0.35) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16400099 0.88 HSD11B1 (0.39) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16400657 0.85 HSD11B1 (0.35) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16400193 0.84 ELANE (0.40) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL17685948 0.82 THRB (0.35) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16399349 0.80 ELANE (0.38) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16400044 0.78 HSD11B1 (0.40) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16401118 0.76 HSD11B1 (0.34) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL16399441 0.74 ELANE (0.40) HSD11B1MAPTALDH1A1HSD17B10ELANE
SCHEMBL17685995 0.73 THRB (0.35) HSD11B1MAPTALDH1A1HSD17B10ELANE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160108027-A1 SUBSTITUTED BENZOXAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-21 US disclosed
US-20160108027-A1 SUBSTITUTED BENZOXAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-21 US disclosed
US-20160108027-A1 SUBSTITUTED BENZOXAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-04-21 US disclosed
EP-3004086-A1 SUBSTITUTED BENZOXAZOLES Bayer Pharma Aktiengesellschaft (DE) 2016-04-13 EP disclosed
WO-2014195230-A1 SUBSTITUTED BENZOXAZOLES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160108027-A1 SUBSTITUTED BENZOXAZOLES TBXA2R, XDH, CYP4X1 HSD11B1 1626/4885MAPT 4644/4885ALDH1A1 724/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.